Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease

Karl Herrup, Maria C. Carrillo, Dale Schenk, Angela Cacace, Susan DeSanti, Robert Fremeau, Ratan Bhat, Marcie Glicksman, Patrick May, Russell Swerdlow, Linda J. Van Eldik, Lisa J. Bain, Samantha Budd

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies.

Original languageEnglish
Pages (from-to)452-458.e1
JournalAlzheimer's and Dementia
Issue number4
StatePublished - Jul 1 2013

Bibliographical note

Funding Information:
We thank Dr. Adam Bachstetter, University of Kentucky, for preparation of the figure. These studies were supported in part by NIH P30 AG028383 (LVE).


  • Alzheimer's disease
  • Amyloid
  • Autophagy
  • Cell cycle
  • Inflammation
  • Metabolism
  • Mitochondria
  • Neuroinflammation
  • Non-amyloid targets
  • Tau
  • Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Health Policy
  • Developmental Neuroscience
  • Epidemiology


Dive into the research topics of 'Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this